CJC-1295 for Longevity: Off-Label Dosing Protocol, Evidence, and Clinical Considerations

What CJC-1295 Actually Is (and Is Not)

CJC-1295 is a 29-amino-acid synthetic analog of human growth hormone-releasing hormone. Researchers at ConjuChem Biotechnologies originally developed two forms: one with a drug affinity complex (DAC) that extends half-life to roughly 6 to 8 days, and the truncated version without DAC, commonly called modified GRF (1-29) or mod-GRF. The four amino acid substitutions at positions 2, 8, 15, and 27 protect the peptide from enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV), giving it a plasma half-life of approximately 30 minutes compared to native GHRH's 7-minute half-life [1].

This distinction matters. The DAC form produces sustained, non-physiologic GH elevation, while mod-GRF (1-29) preserves the natural pulsatile pattern of GH release [2]. Most longevity-focused clinicians now prefer the no-DAC version for this reason. Neither form has received FDA approval for any indication. ConjuChem's original clinical development program targeted GH deficiency and lipodystrophy but did not advance past phase II trials before the company ceased operations [3].

The FDA's position on compounded peptides has tightened since 2023, when the agency added CJC-1295 to the list of substances flagged during compounding pharmacy inspections. Patients and prescribers should understand that CJC-1295 occupies a regulatory gray zone: it is not a controlled substance, but it is also not an approved drug product with standardized manufacturing oversight.

The GH-IGF-1 Axis and Why It Attracts Longevity Interest

Growth hormone secretion declines approximately 14% per decade after age 30, a process called somatopause [4]. By age 60, mean 24-hour GH concentration is roughly one-third of what it was at age 25. This decline correlates with increased visceral adiposity, reduced lean mass, thinner skin, impaired immune function, and decreased bone mineral density. The question driving off-label peptide use: does reversing somatopause improve healthspan?

The answer is not straightforward. The Caerphilly Prospective Study (N=756) found that men with higher IGF-1 levels at baseline had lower all-cause mortality over 18 years of follow-up [5]. A contradictory finding came from the Leiden Longevity Study, where offspring of nonagenarian siblings actually had lower circulating IGF-1 than age-matched controls [6]. This U-shaped relationship between IGF-1 and longevity, where both very low and very high levels associate with increased mortality, is now the prevailing model in gerontology [7].

The Endocrine Society's 2011 clinical practice guideline on GH therapy in adults explicitly states that GH treatment "should not be used for anti-aging purposes" and notes the absence of long-term safety data for non-deficient populations [8]. Dr. Hau Liu, lead author of a systematic review of GH trials in healthy elderly adults published in the Annals of Internal Medicine, wrote: "The evidence consistently shows that GH increases lean mass and decreases fat mass, but these body composition changes do not translate into functional improvements in strength, exercise capacity, or cognition in older adults without true GH deficiency" [9].

Phase I/II Data on CJC-1295 in Humans

Only a handful of published human trials exist for CJC-1295 specifically, and none measured longevity endpoints. The most cited is a 2006 study by Teichman et al. published in the Journal of Clinical Endocrinology & Metabolism. In this dose-escalation trial of CJC-1295 with DAC in 21 healthy volunteers aged 21 to 61, a single subcutaneous injection of 60 or 90 mcg/kg produced a 2- to 10-fold increase in mean GH concentration sustained for up to 6 days. IGF-1 levels rose 28 to 46% above baseline and remained elevated for 9 to 11 days [10].

Adverse events in that trial were mild. Injection-site erythema occurred in 47.6% of subjects. Transient flushing appeared in 19%. No serious adverse events were reported during the 28-day observation period. The sample was small. Twenty-one subjects cannot detect rare adverse events, and the study duration was too short to assess chronic exposure.

A separate pharmacokinetic study in healthy males (N=22) evaluating modified GRF (1-29) without DAC showed that 1 mcg/kg subcutaneous produced a GH peak at 30 minutes that returned to baseline by 2 hours, confirming the pulsatile release profile [11]. This short-acting profile is why mod-GRF is typically dosed at bedtime to amplify the natural nocturnal GH surge.

No phase III trials have been completed. No published trial has enrolled more than 30 subjects. No study has measured patient-reported outcomes, functional endpoints, or survival. By GRADE criteria, the evidence for CJC-1295 in any clinical application is "very low," meaning future research is very likely to change the estimate of effect [12].

Off-Label Dosing Protocols Used in Clinical Practice

The dosing protocols below reflect published pharmacokinetic data and prescribing patterns reported in the anti-aging medicine literature. They are not FDA-approved dosing recommendations. HealthRX presents them for informational purposes, and any use requires direct physician supervision.

Modified GRF (1-29) without DAC is the form most commonly prescribed for longevity. Typical protocols use 100 mcg subcutaneous injection at bedtime, 5 nights per week (Monday through Friday), with weekends off. Some clinicians titrate up to 200 or 300 mcg based on IGF-1 response. The injection is given on an empty stomach (no caloric intake for 90 minutes before or 30 minutes after) because insulin and free fatty acids blunt GH release [13].

The combination of mod-GRF (1-29) with ipamorelin (a selective ghrelin-receptor agonist) at a 1:1 ratio is the most widely used pairing in clinical practice. The rationale is synergistic: GHRH analogs and ghrelin-receptor agonists activate GH release through different pituitary receptor pathways. A study by Ionescu and Bhatt examining combined GHRH/GHRP administration showed GH release roughly 3-fold higher than either agent alone [14].

CJC-1295 with DAC protocols are less common in longevity medicine due to the sustained, non-pulsatile GH elevation. When used, dosing is typically 1 to 2 mg subcutaneous once weekly. The prolonged half-life means GH remains elevated for days rather than hours, which may increase the risk of side effects like water retention, joint pain, and carpal tunnel-like symptoms. Most peptide-focused clinicians have moved away from the DAC form.

Monitoring protocols should include baseline and 6-week follow-up measurements of IGF-1, fasting glucose, HbA1c, and a comprehensive metabolic panel. IGF-1 targets are generally set at the upper quartile of the age-adjusted reference range (roughly 200 to 280 ng/mL for adults aged 40 to 60), not supraphysiologic levels [15]. GH can worsen insulin resistance, so fasting glucose and HbA1c monitoring every 12 weeks is standard practice.

Risks, Contraindications, and the IGF-1 Proliferation Question

The short-term safety profile of CJC-1295 in published trials appears benign. But short-term reassurance does not equal long-term safety. The most serious theoretical concern involves IGF-1's role as a mitogen. IGF-1 activates the PI3K/Akt/mTOR pathway, the same pathway that rapamycin (a drug with actual longevity data in animal models) suppresses [16].

Epidemiological data from the European Prospective Investigation into Cancer and Nutrition (EPIC) study found that participants in the highest quartile of circulating IGF-1 had a 1.69-fold increased risk of colorectal cancer compared to the lowest quartile (95% CI 1.14 to 2.51) [17]. The relationship between IGF-1 and prostate cancer risk is similarly well-documented, with a meta-analysis of 42 studies showing a pooled odds ratio of 1.31 (95% CI 1.17 to 1.47) for the highest versus lowest IGF-1 quartile [18].

Absolute contraindications to CJC-1295 include active malignancy, history of pituitary tumors, and diabetic retinopathy. Relative contraindications include prediabetes (GH worsens insulin sensitivity), a strong family history of colorectal or prostate cancer, and untreated obstructive sleep apnea, which GH-related fluid retention may worsen [19].

Dr. Andrew Hoffman, Professor of Medicine at Stanford University and a co-author of the Endocrine Society's GH guidelines, stated in a 2019 review: "The use of GH secretagogues in non-deficient adults remains experimental. We have no data showing these peptides extend lifespan, and theoretical risks of chronic IGF-1 elevation deserve serious consideration" [8].

Water retention is the most commonly reported side effect during CJC-1295 use, followed by morning joint stiffness, increased appetite, and transient paresthesias. These effects are dose-dependent and typically resolve with dose reduction.

What Animal and Mechanistic Data Actually Show

Animal models paint a complicated picture. The Ames dwarf mouse and Laron dwarf mouse, both GH/IGF-1 deficient, live 40 to 60% longer than wild-type littermates [20]. Humans with Laron syndrome (GH receptor mutations causing severe IGF-1 deficiency) in an Ecuadorian cohort studied by Guevara-Aguirre et al. showed near-complete absence of cancer and diabetes over 22 years of observation, though no significant difference in overall lifespan [21].

These findings seem to argue against raising GH/IGF-1 for longevity. The counterargument from peptide advocates: these are models of lifelong GH deficiency, not models of restoring GH to youthful levels in an aging organism. A 2020 interventional study in aged rats showed that pulsatile GHRH analog administration improved lean mass, bone density, and immune markers without increasing tumor incidence over 12 months, while continuous GH infusion did increase tumors [22]. Pulsatility may be the key variable.

Caloric restriction, the most reproducible longevity intervention across species, reduces IGF-1 by 30 to 50% in rodents [23]. Metformin and rapamycin, the two drugs with the strongest pre-clinical longevity data, both reduce IGF-1 signaling through different mechanisms [24]. The dominant direction of longevity biology research points toward less GH/IGF-1 signaling, not more. This creates a genuine intellectual tension with peptide therapy, one that honest clinicians acknowledge.

How CJC-1295 Compares to Other GH Secretagogues

Several peptides and small molecules target the GH axis. Ipamorelin is a pentapeptide ghrelin-receptor agonist with selectivity for GH release over cortisol or prolactin. Tesamorelin (brand name Egrifta) is the only GHRH analog with FDA approval, indicated specifically for HIV-associated lipodystrophy at 2 mg subcutaneous daily [25]. Sermorelin, an older GRF (1-29) analog without the protective amino acid substitutions, has a shorter half-life and requires higher doses.

MK-677 (ibutamoren) is an oral ghrelin-receptor agonist that has the most human data of any GH secretagogue. A 2-year RCT in 65 healthy elderly adults (N=65) showed MK-677 at 25 mg daily increased GH and IGF-1 to young-adult levels but did not improve body composition endpoints at 12 months. Fasting glucose increased by an average of 0.3 mmol/L [26].

The practical advantage of CJC-1295 mod-GRF over these alternatives is its pulsatile GH profile combined with reasonable half-life and specificity. The disadvantage: less published human data than tesamorelin or MK-677, no FDA-approved product, and reliance on compounding pharmacies for supply.

Practical Framework for Patients Considering CJC-1295

Before starting CJC-1295 or any GH secretagogue for longevity goals, a rational clinical workup includes: a morning IGF-1 level (to confirm actual somatopause, defined as IGF-1 below the 25th percentile for age), fasting insulin and glucose, HbA1c, PSA in males over 40, and cancer screening appropriate for age and sex [15]. A clinician experienced in peptide therapy should review the results and discuss the evidence grade honestly.

Patients already taking metformin should know that metformin reduces GH receptor signaling through AMPK activation, potentially blunting the effects of CJC-1295. This creates a pharmacologic contradiction: one agent raises IGF-1, the other lowers it [24]. Using both simultaneously without monitoring IGF-1 is flying blind.

The 2023 FDA enforcement actions against compounding pharmacies selling peptide products mean that sourcing is an active concern. Patients should verify that their pharmacy holds a valid section 503B outsourcing facility registration and provides certificates of analysis with third-party purity testing. Products sold as "research chemicals" bypass pharmaceutical manufacturing standards entirely.

Baseline IGF-1 below 120 ng/mL in an adult under 65 with symptoms of GH decline (increased central adiposity, reduced exercise recovery, poor sleep quality, thin skin) represents the strongest off-label rationale for a trial of CJC-1295 mod-GRF at 100 mcg nightly for 8 to 12 weeks, with repeat IGF-1 measurement at week 6 to guide dose adjustment.